Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 10:14:1191-1204.
doi: 10.2147/TCRM.S159134. eCollection 2018.

A meta-analysis and systematic review evaluating the use of erythropoietin in total hip and knee arthroplasty

Yi Li #  1 , Pengbin Yin #  1 , Houchen Lv  1 , Yutong Meng  1 , Licheng Zhang  1 , Peifu Tang  1
Affiliations
Review

A meta-analysis and systematic review evaluating the use of erythropoietin in total hip and knee arthroplasty

Yi Li et al. Ther Clin Risk Manag. .

Abstract

Purpose: The debate is still ongoing on the effectiveness and safety of erythropoietin (EPO) treatment in orthopedic surgeries. Specifically, previous studies have not compared the dynamic change of hemoglobin (Hb) levels between different transfusion methods. Besides, complications or side effects of this alternative have not been quantitatively analyzed. We conducted a meta-analysis and systemic review to evaluate the efficacy of EPO on Hb levels observed during the whole perioperative period as well as the volume of allogeneic blood transfusion (ABT), the risk of venous thromboembolism, and application frequency of ABT in hip and knee surgery.

Materials and methods: PubMed, Embase, Web of Science, and the Cochrane library were systematically searched from inception to November 2017. The data from randomized controlled trials were extracted and the risk of bias assessed using Cochrane's Collaboration's tool.

Results: Twenty-five randomized controlled trials involving 4,159 patients were included in this meta-analysis. EPO could reduce exposure to allogeneic blood transfused (odds ratio [OR] =0.42, P=0.001) and reduce the average volume of allogeneic blood transfused (OR = -0.28, P=0.002). When EPO and preoperative autologous blood donation (PABD) were compared, the use of EPO was associated with lower exposure to ABT (OR =0.48, P=0.03), but no significant decrease in the average volume of allogeneic blood transfused (OR = -0.23, P=0.32). The use of EPO was associated with a higher level of Hb with or without use of PABD at all the 4 time points (preoperation, 24-48 hours postoperation, 3-5 days postoperation, discharge of last observation) (P<0.0001), which means EPO could increase the level of Hb significantly during the perioperative period. The results also indicated EPO does not increase the risk of a venous thromboembolism event.

Conclusion: Preoperative administration of EPO was shown to generally increase Hb levels during the whole perioperative period; however, the extent of the positive effects varies with time points. Additionally, EPO minimizes the need for transfusion significantly in patients undergoing hip or knee surgery without increasing the chance of developing thrombotic complications. Therefore, EPO offers an alternative blood management strategy in total hip arthroplasty and total knee arthroplasty.

Keywords: allogeneic transfusion; autologous blood donation; erythropoietin; hemoglobin; total hip arthroplasty; total knee arthroplasty.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Risk of bias summary. Notes: QUADAS-2 was used to analysis the quality of including trials. The green circles mean “Yes.” Yellow circles mean “Unsure” and red circles mean “No.” Abbreviation: QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies-2.
Figure 2
Figure 2
Study flow diagram. Abbreviation: RCT, randomized controlled trial.
Figure 3
Figure 3
Patients needing ABT. Abbreviations: ABT, allogeneic blood transfusion; EPO, erythropoietin; M–H, Mantel–Haenszel; OR, odds ratio; PABD, preoperative autologous blood donation.
Figure 4
Figure 4
Units of allogeneic blood transfused. Abbreviations: EPO, erythropoietin; PABD, preoperative autologous blood donation.
Figure 5
Figure 5
Preoperative Hb. Abbreviations: EPO, erythropoietin; Hb, hemoglobin; PABD, preoperative autologous blood donation.
Figure 6
Figure 6
Hb levels 24–48 hours postsurgery. Abbreviations: EPO, erythropoietin; PABD, preoperative autologous blood donation.
Figure 7
Figure 7
Hb levels 3–5 days postsurgery. Abbreviations: EPO, erythropoietin; Hb, hemoglobin; PABD, preoperative autologous blood donation.
Figure 8
Figure 8
Hb level at discharge/last observation. Abbreviations: EPO, erythropoietin; Hb, hemoglobin; PABD, preoperative autologous blood donation.
Figure 9
Figure 9
TKA patients needing ABT. Abbreviations: ABT, allogeneic blood transfusion; EPO, erythropoietin; M–H, Mantel–Haenszel; OR, odds ratio; PABD, preoperative autologous blood donation; TKA, total knee arthroplasty.
Figure 10
Figure 10
THA patients needing ABT. Abbreviations: ABT, allogeneic blood transfusion; EPO, erythropoietin; M–H, Mantel–Haenszel; OR, odds ratio; PABD, preoperative autologous blood donation; THA, total hip arthroplasty.
Figure 11
Figure 11
The risk of VTE. Abbreviations: EPO, erythropoietin; M–H, Mantel–Haenszel; OR, odds ratio; PABD, preoperative autologous blood donation; VTE, venous thromboembolism.
See this image and copyright information in PMC

References

    1. Tran DHD, Wong GT, Chee YE, Irwin MG. Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period. Expert Opin Biol Ther. 2014;14(1):51–61. - PubMed
    1. Zhao Y, Jiang C, Peng H, Feng B, Li Y, Weng X. The effectiveness and safety of preoperative use of erythropoietin in patients scheduled for total hip or knee arthroplasty. Medicine. 2016;95(27):e4122. - PMC - PubMed
    1. Voorn VMA, van der Hout A, So-Osman C, et al. Erythropoietin to reduce allogeneic red blood cell transfusion in patients undergoing total hip or knee arthroplasty. Vox Sang. 2016;111(3):219–225. - PubMed
    1. Alsaleh K, Alotaibi GS, Almodaimegh HS, Aleem AA, Kouroukis CT. The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty. J Arthroplasty. 2013;28(9):1463–1472. - PubMed
    1. Stivelman JC. Target-based anemia management with erythropoiesis stimulating agents (risks and benefits relearned) and iron (still more to learn) Semin Dial. 2017;30(2):142–148. - PubMed